VivoSeq
Gastroenterology

IBS

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

IBS is an early-stage landscape with 0 programs across 2 companies. The most active players are Dynogen Pharmaceuticals, Theriva Biologics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

D

Dynogen Pharmaceuticals

0 programs

PreclinicalT

Theriva Biologics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

13

clinical trials

Completed8 · 62%
Unknown status2 · 15%
Recruiting2 · 15%
Terminated1 · 8%

Clinical Trials

Trial Activity

13 trials

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
Recruiting·AArdelyx·Phase 2·NCT06553547·72 enrolled
Ebastine Versus Mebeverine in IBS Patients
Recruiting·—·Phase 3·NCT05815602·200 enrolled
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c
Completed·DDynogen Pharmaceuticals·Phase 2·NCT00215566·90 enrolled
Comparative Bioavailability Study of Human Chorionic Gonadotropin (hCG)-IBSA Versus a Marketed hCG Formulation
Completed·IIBSA Institut Biochimique SA·Phase 1·NCT03735030·26 enrolled
A Study of the Effect of SYN-010 on Subjects With IBS-C
Completed·TTheriva Biologics, Inc.·Phase 2·NCT02495623·63 enrolled
Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D
Completed·CCosmo Technologies Ltd·Phase 2·NCT03099785·279 enrolled
Stability of the Microbiome in IBD and IBS
Completed·MMedical University of Graz·N/A·NCT03395548·50 enrolled
FMT for Post-infectious IBS
Completed·—·N/A·NCT05461833·59 enrolled
Cheno Effect on Transit in Health and IBS-C
Completed·MMayo Clinic·Phase 2·NCT00912301·36 enrolled
The Effect of Neu-P11 on Symptoms in Patients With D-IBS
Completed·LLudwig-Maximilians - University of Munich·N/A·NCT01558284·40 enrolled
Effect of a Probiotic Formula on Reducing SIBO in IBS Patients
Terminated·AAB Biotics, SA·N/A·NCT04316806·8 enrolled
Effect of Butyrogenic Fibers in IBS Patients
Unknown status·UUniversity Hospital, Clermont-Ferrand·N/A·NCT00314886·15 enrolled
Ethosuximide to Treat IBS
Unknown status·UUniversity Hospital, Clermont-Ferrand·Phase 2·NCT02973542·162 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)